Skip to main content
. 2022 Nov 17;13:1259–1270. doi: 10.18632/oncotarget.28310

Table 2. Participant cancer and cancer treatment history (n = 126).

Genotype
E2− E2+ E4− E4+
Cancer type n (%)
 Breast 77 (71) 10 (59) 67 (69) 20 (69)
 Cervical 3 (3) 0 (0) 1 (1) 2 (7)
 Colon 6 (6) 2 (12) 6 (6) 2 (7)
 Lung 3 (3) 2 (12) 5 (5) 0 (0)
 Lymphoma 5 (5) 1 (6) 4 (4) 2 (7)
 Ovarian 6 (6) 1 (6) 6 (6) 1 (3)
 Uterine 5 (5) 1 (6) 4 (4) 2 (7)
 Other 4 (4) 0 (0) 4 (4) 0 (0)
Cancer stage
 I 29 (27) 6 (35) 24 (25) 11 (38)
 II 39 (36) 4 (24) 34 (35) 9 (31)
 III 30 (28) 5 (29) 30 (31) 5 (17)
 IV or metastatic 0 (0%) 0 (0) 0 (0%) 0 (0)
 No stage/don’t remember 11 (10) 2 (12) 9 (9) 4 (14)
Cancer treatment received 108 (99) 16 (94) 96 (99) 28 (97)
 Chemotherapy 109 (100) 17 (100) 97 (100) 29 (100)
 Surgery 99 (91) 13 (76) 85 (88) 27 (93)
 Radiation 74 (68) 9 (53) 63 (65) 20 (69)
 Hormone therapy 40 (37) 3 (18) 33 (34) 10 (34)
Diagnosed with any other type of cancer? 21 (19) 3 (18) 21 (22) 3 (10)
Total 109 (100) 17 (100) 97 (100) 29 (100)